REG - Diaceutics PLC - PDMR Shareholding/Share Incentive Plan

DiaceuticsAnnouncement

02/03/2022 17:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220302:nRSB4462Da&default-theme=true

RNS Number : 4462D  Diaceutics PLC  02 March 2022

 

 2 March 2022

Diaceutics PLC

("Diaceutics" or "the Company")

 

PDMR Shareholding/Share Incentive Plan

 

Diaceutics PLC (https://www.diaceutics.com/) , (AIM: DXRX), the diagnostic
commercialisation company has been notified that on 28 February 2022
Yorkshire Building Society purchased, and on 1 March 2022 Zedra Trust Company
(Guernsey) Limited, the trustees of the Global Diaceutics plc 2020 Employee
Benefit Trust purchased ordinary shares ("Shares"), on behalf of Stefan
Macdonald and Susanne Munksted respectively (PDMRs), in respect of their
purchase of Shares pursuant to the Company's UK and Global Share Incentive
Plan ("the SIP Schemes") for  employees. These purchases will be made each
month until further notice.

 

In accordance with the SIP Schemes, the Company has matched these purchases
with a matched share award over an equivalent number of Shares purchased by
the employee, in the proportion of 2:1.

 

 

Enquiries:

 Diaceutics PLC
 Philip White, Chief Financial Officer                Via Alma PR

 Stifel Nicolaus Europe Limited (Nomad & Broker)      Tel: +44 (0)20 7710 7600
 Ben Maddison
 Stewart Wallace
 Nick Adams

 Alma PR                                              Tel: +44(0)20 3405 0205
 Caroline Forde                                       diaceutics@almapr.co.uk
 Kieran Breheny
 Matthew Young

About Diaceutics

 

At Diaceutics we believe that every patient should have access to the right
treatment at the right time. We provide the world's leading pharmaceutical
companies with an end-to-end solution for the launch of precision medicine
diagnostics enabled by DXRX - The Diagnostic Network®.

 

DXRX is the world's first diagnostic commercialisation platform for precision
medicine, integrating multiple pipelines of real-world diagnostic testing data
from a global network of laboratories.

 

 

 

 

 

 Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
 596/2014
 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name                                                         Stefan Macdonald
 2   Reason for notification
 a.  Position/Status                                              Global Growth Officer and PDMR
 b.  Initial notification/                                        Initial

     Amendment
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         Diaceutics PLC
 b.  LEI                                                          213800VEWQBB39ZB8J81
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument  Ordinary shares of £0.002 each

Identification Code

                                                                  ISIN:  GB00BJQTGV64
 b.  Nature of the transaction                                    Ongoing non-discretionary purchase of Shares matched by the grant of
                                                                  conditional share award over Shares under the Diaceutics plc UK Share
                                                                  Incentive Plan ("SIP")
 c.  Price(s) and volume(s)                                                     Share purchase:
                                                                                Price(s)      Volume(s)
     0.998 p                                                                                  151
                                                                                                             Matched share award:
                                                                                Price(s)      Volume(s)
                                                                                0.998 p       302

 e.  Date of the transaction                                      Share purchase and Matched Share award: 28 January 2022
 f.  Place of the transaction                                     Share Purchase and Matched Share Award: AIM Market of the London Stock
                                                                  Exchange

 

 

 Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
 596/2014
 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name                                                         Susanne Munksted
 2   Reason for notification
 a.  Position/Status                                              Chief Precision Medicine Officer and PDMR
 b.  Initial notification/                                        Initial

     Amendment
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         Diaceutics PLC
 b.  LEI                                                          213800VEWQBB39ZB8J81
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument  Ordinary shares of £0.002 each

Identification Code

                                                                  ISIN:  GB00BJQTGV64
 b.  Nature of the transaction                                    Ongoing non-discretionary purchase of Shares matched by the grant of
                                                                  conditional share award over Shares under the Global Share Incentive Plan
                                                                  ("SIP")
 c.  Price(s) and volume(s)                                                      Share purchase:
                                                                                 Price(s)       Volume(s)
     1.01 p                                                                                     134
                                                                                                               Conditional share award:
                                                                                 Price(s)       Volume(s)
                                                                                 Nil            268

 e.  Date of the transaction                                      Share purchase and Conditional share award: 1 March 2022
 f.  Place of the transaction                                     Share Purchase: AIM Market of the London Stock Exchange

                                                                  Conditional share award: Off-Market

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBKBBNOBKDANK